Chiang, C. Y.; Pratuseviciute, N.; Lin, Y.-E.; Adhikari, A.; Yeshaw, W. M.; Flitton, C.; Sherpa, P. L.; Tonelli, F.; Rektorova, I.; Lynch, T.; Siuda, J.; Rudzinska-Bar, M.; Pulyk, O.; Bauer, P.; Beetz, C.; Dickson, D. W.; Ross, O. A.; Wszolek, Z.; Klein, C.; Zimprich, A.; Alessi, D. R.; Sammler, E. M.; Pfeffer, S. R.

Leucine-rich repeat kinase 2 (LRRK2) phosphorylates a subset of Rab GTPases that regulate receptor trafficking; activating mutations in LRRK2 are linked to Parkinsons disease. Rab phosphorylation is a transient event that can be reversed by phosphatases, including PPM1H, that acts on phosphoRab8A and phosphoRab10. Here we report a phosphatome-wide siRNA screen that identified PPM1M as a phosphoRab12-preferring phosphatase that also acts on phosphoRab8A and phosphoRab10. Upon knockout from cells or mice, PPM1M displays selectivity for phosphoRab12. As shown previously for mice harboring LRRK2 pathway mutations, knockout of Ppm1m leads to primary cilia loss in striatal cholinergic interneurons. We have also identified a rare PPM1M mutation in patients with Parkinsons disease that is catalytically inactive when tested in vitro and in cells. These findings identify PPM1M as a key player in the LRRK2 signaling pathway and provide a new therapeutic target for the possible benefit of patients with Parkinsons disease.